Table 1

Summary of BP and renal function in young adult conscious chronically catheterized male Sprague-Dawley rats studied in control and then during one of the following experimental (Exp) maneuvers.

BPRVRGFRRPFFFVUNaVFENaUKV
mm Hg mm Hg (ml/min) ml/min ml/min μl/min μeq/min % μeq/m
Group 1
 Control (n = 8)119  ± 25.5  ± 0.53.01  ± 0.0812.6  ± 1.00.251  ± 0.02121.3  ± 4.02.40  ± 0.530.564  ± 0.1142.64  ± 0.24
 Exp (+NAME)154  ± 313.0  ± 0.82.40  ± 0.186.8  ± 0.40.359  ± 0.01767.2  ± 13.75.34  ± 1.351.629  ± 0.3812.45  ± 0.21
 p, c vs. exp<0.001<0.001<0.005<0.001<0.001<0.01<0.05<0.001N.S.
Group 2
 Control (n = 7)121  ± 15.6  ± 0.32.99  ± 0.1711.9  ± 0.60.254  ± 0.01315.9  ± 2.01.77  ± 0.280.432  ± 0.0702.28  ± 0.20
 Exp (NAME + prazosin)153  ± 215.6  ± 0.91.89  ± 0.095.5  ± 0.30.345  ± 0.01327.0  ± 6.2*1.69  ± 0.65*0.624  ± 0.207*1.74  ± 0.13*
 p, c vs. exp<0.001<0.001<0.001<0.001<0.005N.S.N.S.N.S.<0.01
Group 3
 Control (n = 6)121  ± 15.9  ± 0.32.75  ± 0.1411.1  ± 0.60.251  ± 0.01717.9  ± 2.61.47  ± 0.240.390  ± 0.0672.11  ± 0.19
 Exp (NAME + prazosin +  losartan)130  ± 5a 12.9  ± 1.01.96  ± 0.165.6  ± 0.30.356  ± 0.02115.6  ± 1.6*1.17  ± 0.22*0.494  ± 0.129*1.83  ± 0.14a
 p, c vs. expN.S.<0.001<0.01<0.001<0.005N.S.N.S.N.S.N.S.
Group 4
 Control (n = 7)117  ± 24.8  ± 0.53.58  ± 0.1513.6  ± 1.070.271  ± 0.02014.5  ± 1.41.56  ± 0.320.308  ± 0.0673.32  ± 0.36
 Exp (prazosin + losartan)88  ± 23.4  ± 0.33.07  ± 0.0814.9  ± 0.90.211  ± 0.0178.3  ± 0.41.32  ± 0.230.297  ± 0.0492.46  ± 0.13
 p, c vs. exp<0.001<0.001<0.005<0.05<0.001<0.01N.S.N.S.<0.05
Group 5
 Control (n = 7)114  ± 14.4  ± 0.33.36  ± 0.2214.5  ± 1.00.234  ± 0.00814.7  ± 1.61.71  ± 0.230.369  ± 0.0623.35  ± 0.34
 Exp (prazosin + losartan  + NAME delayed)131  ± 28.3  ± 0.82.74  ± 0.159.4  ± 1.10.302  ± 0.01428.8  ± 6.73.55  ± 0.770.930  ± 0.2232.73  ± 0.15
 p, c vs. exp<0.005<0.001<0.01<0.005<0.025<0.05N.S.<0.05N.S.

Group 1 rats received nonselective NO synthesis inhibitorl-NAME (i.v., 10 mg/kg), group 2 receivedl-NAME + concomitant alpha adrenoceptor blockade with prazosin (i.v., 0.1 mg/kg), and group 3 receivedl-NAME, prazosin and angiotensin II AT1 receptor blockade with losartan (i.v. 3 mg/kg) all given simultaneously. Group 4 received prazosin and losartan together and group 5 received prazosin and losartan initially and then l-NAME after a 25-min delay.

  • Values are mean ± S.E. p values are paired differences within each group. * Denotes a significant difference (p < 0.05) in experimental period of group 1 vs. group 2 or group 1 vs. group 3. a Denotes a difference in experimental period between groups 2 and 3. FENa, fractional excretion of sodium.